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In economically developed countries, AIDS-related lymphoma (ARL) accounts for a large proportion of malignances in HIV-
infected individuals. Since the introduction of highly active anti-retroviral therapy (HAART) in 1996, epidemiology and prognosis
of ARL have changed. While there is a slight increase in the incidence of Hodgkin’s lymphoma in HIV-infected individuals,
use of HAART has contributed to a decline in the incidence of non-Hodgkin’s lymphoma (NHL) and also a decrease in the
overall incidence of ARL. Strategies that employ HAART, improved supportive care, and the use of Rituximab with multi-agent
chemotherapy have contributed to improved rates of complete remission and survival of patients with ARL that rival those seen
in stage and histology matched HIV negative NHL patients. Most recent clinical trials demonstrate better outcomes with the
use of rituximab in ARL. Tumor histogenesis (germinal center vs. non-germinal center origin) is associated with lymphoma-
speciﬁc outcomes in the setting of AIDS-related diﬀuse-large B cell lymphoma. High-dose chemotherapy (HDCT) and autologous
stem cell rescue (ASCT) can be eﬀective for a subset of patients with relapsed ARL. HIV sero-status alone should not preclude
consideration of ASCT in the setting of ARL relapse. Clinical trials investigating the role of allogeneic hematopoietic stem cell
transplant in ARL are currently underway.
1.Introduction
Non-Hodgkin’s lymphoma (NHL) has been associated with
human immunodeﬁciency virus (HIV) infections since the
beginning of the acquired immune deﬁciency syndrome
(AIDS) epidemic. The initial case deﬁnition of AIDS by the
US Centers for Disease Control and Prevention (CDC) in
1982 included AIDS-deﬁning malignancies such as Kaposi’s
sarcoma and primary central nervous system lymphoma
(PCNSL), with subsequent inclusion of peripheral interme-
diate and high-grade B-cell NHL [1]. People living with
HIV/AIDS (PLWA) are also at a signiﬁcantly greater risk
of developing Hodgkin’s disease compared to the general
population but this has not yet been added to the CDC case
deﬁnition of AIDS [2].
HIV seropositivity increases the risk of developing NHL
by 60–165-fold [3, 4]. AIDS-related lymphomas (ARLs) tend
to present with high-grade B-cell histology, advanced-stage
disease, and an aggressive clinical course. Prior to the advent
of highly active antiretroviral therapy (HAART) in 1996,
ARL was associated with a dismal prognosis, particularly in
those patients who had compromised performance status,
advanced immune dysfunction, and limited hematopoietic
reserve. With the introduction of HAART, the survival of
patients with ARL has improved substantially and appears
to be comparable to that of their HIV-negative NHL coun-
terparts. Advances in chemotherapy regimens, antiretroviral
drugs, and supportive care have led to more aggressive man-
agement of ARL compared to the pre-HAART era. Several
ARL chemotherapy trials have incorporated the anti-CD20
monoclonalantibodyrituximabwithmultiagentchemother-
apy; however, optimal therapy of ARL is still not clearly
deﬁned [5–12].
In this paper, we highlight several current strategies
for treatment of AIDS-related non-Hodgkin’s lymphoma
including speciﬁc systemic chemo-biologic therapies. We2 Advances in Hematology
alsobrieﬂyreviewvariousprognostictoolsandfactorswhich
inﬂuence therapeutic outcomes and potential for treatment-
related toxicities. We do so through a systematic review
of peer-reviewed publications identiﬁed through searches
of MEDLINE/PubMed from July 2005 to June 2011. The
ongoing phase II and phase III trials for ARL were searched
from the US National Institute of Health’s web resource,
http://clinicaltrials.gov/,aregistryofclinicaltrialsconducted
in the United States and worldwide. Keywords were used
alone and with the modiﬁers of treatment, novel thera-
pies, AIDS-related lymphoma, prognostic and biomarkers,
and HIV/AIDS. Bibliographies from these references were
reviewed. Criteria used for study selection included study
design, English language, and relevance to clinicians.
2. Pathobiology of ARL
ARL are comprised of a narrow spectrum of histologic types
consisting almost exclusively of aggressive B-cell tumors,
derivedfromeithergerminalcentersorpostgerminalcenters.
While majority of tumors are diﬀuse large B-cell lymphomas
(DLBCLs), a few ARL are B-cell immunoblastic lymphomas
and Burkitt’s or Burkitt’s-like small noncleaved lymphoma.
Even more rare are PCNSLs. The World Health Organization
has classiﬁed HIV-related lymphomas into three categories:
lymphomas also occurring in immunocompetent patients,
those speciﬁcally occurring in HIV-positive patients, and
those occurring in other immunodeﬁciency states (Table 1)
[13].
HIV creates a milieu of combined immune suppression
and chronic antigenic stimulation in lymph nodes [14].
Thisenvironmentwithdysregulatedcytokinereleaseandim-
paired dendritic function, along with presence of concomi-
tant infection (e.g., Epstein Barr Virus [EBV], Human Her-
pes Virus type 8 (HHV-8), and cytomegalovirus) may pro-
mote a permissive environment for HIV-induced polyclonal
B-cell expansion and impaired T-cell immunosurveillance,
culminating in lympho-proliferative disorders [15].
The cytokine proﬁle of HIV-infected individuals at risk
for ARL demonstrates increased markers of B-cell acti-
vation such as interleukin- (IL-) 6, IL-10, and soluble
CD-30 compared to HIV-positive controls who do not
develop ARL [16]. Although the molecular mechanisms
responsible for B-cell transformation associated with ARL
have not been completely elucidated, many diﬀerent ARL-
associated molecular lesions have been described, includ-
ing chromosome translocation and activation of the C-
MYC oncogene, inactivation of p53 tumor-suppressor gene,
somatic mutations in Bcl-6, and overexpression of EBV
oncoprotein 4 (e.g., latency membrane proteins 1 and 2).
These chromosome breaks and/or molecular lesions likely
have signiﬁcant downstream eﬀects which lead to impaired
lymphocyte diﬀerentiation and cell-cycle control [15, 17].
Recently,preclinicalstudiesandgenome-wideDNAproﬁling
of ARL demonstrated that B-cell-receptor-related signaling
is frequently disrupted in DLBCL tumor tissues of PLWA
compared to DLBCL in immunocompetent patients. This
suggests HIV-associated B-cell dysregulation, and aberrant
Table 1: Who Classiﬁcation of lymphoid malignancies associated
with HIV infection.
Lymphomas also occurring in immunocompetent patients
Burkitt and Burkitt-like lymphomas
Diﬀuse large B-cell lymphomas
Centroblastic
Immunoblastic (including primary CNS lymphoma)
Extranodal MALT lymphoma (rare)
Peripheral T-cell lymphoma (rare)
Classical Hodgkin lymphoma
Lymphoma occurring more speciﬁcally in HIV-positive patients
Primary eﬀusion lymphoma
Plasmablastic lymphoma of the oral cavity
Lymphoma occurring in other immunodeﬁciency states
Polymorphic B-cell lymphoma (PTLD-like) (rare)
MALT: marginal zone lymphoma of mucosa-associated lymphoid tissue;
PTLD: posttransplant lymphoproliferative disorder; CNS: central nervous
system.
Source: [13].
tumor-speciﬁc intracellular signaling may be important in
promotingasubsetofARLs[18,19].UseofHAARThasbeen
associatedwithasigniﬁcantreductioninARLrisk[4,20,21].
HAARTmaymodifylymphomagenicstimuliinseveralways,
such as improving responsiveness of EBV-speciﬁc cytotoxic
T-cell lymphocytes, increasing EBV-speciﬁc antibodies, and
stabilizing immune perturbations that may contribute to B-
cell proliferation [19, 22].
3. Prognostic Factors for
AIDS-RelatedLymphoma inthe
Pre-HAARTand HAARTEra
Early in the AIDS epidemic the clinical course of ARL
was dominated by advanced stage disease, concomitant and
life-threatening opportunistic infections (OIs), and poor
response to treatment. Eﬀorts to treat patients with ARL
using aggressive and complex chemotherapy regimens led
to unacceptable toxicity and early death while low-dose
chemotherapy regimens yielded modest beneﬁt—only 10%
of patients survived for 2 years [6]. Various treatments led to
dismal outcomes with the majority of patients succumbing
to advancing NHL or superimposed OIs [7, 23–25]. Adverse
prognostic factors for ARL included a CD4+ count of less
than 100cells/µL, age older than 35, history of injection
drug use, poor performance status, elevated serum lactate
dehydrogenase (LDH), advanced stage of disease, and prior
AIDS diagnosis [26]. Expectations for survival were dismal
with a median overall survival (OS) of 46 weeks in “good
prognosis” patients with a score of 0 or 1 and just 18 weeks
in “poor prognosis” patients with a score of 3 or 4.
Control of HIV viral replication through HAART has
emerged as a major positive prognostic factor for patients
with ARL with several studies showing dramatic improve-
ments in OS among those who received HAART [27–30].
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age, performance status, tumor state, serum LDH, and the
number of sites of extranodal disease is a useful means of
stratifying risk in aggressive lymphoma in both the non-
HIV and HIV settings [31, 32]. In the HAART era, further
reﬁnements to prognostic factors have incorporated CD4+
c e l lc o u n t st oI P Ia sw e l la su s eo fe ﬀective HAART. A multi-
variate analysis in patients with ARL showed that those with
the most favorable IPI and a CD4+ count of >100cells/µL
had a predicted 1-year survival of 82% compared to 15% in
those with an unfavorable IPI and CD4+ count <100cells/µL
[33]. Furthermore, in a retrospective study of 192 patients,
the complete response rates and the median OS for ARL
had improved to 57% and 43.2 months, respectively, in the
HAART era compared to 32% and 8.3 months in the pre-
HAART era [30]. The importance of HAART and CD4+ cell
countwasalsounderscoredinaprospectivestudyof485ARL
patients undergoing risk-adaptive intensive chemotherapy
[24]. A time-dependent covariates analysis showed that
the signiﬁcant factors for OS were HAART therapy, HIV
score (based on performance status, prior AIDS diagnosis,
and CD4+ count <100cells/µL), and the IPI [24]. More
recently, a report by the Collaboration of observational HIV
epidemiological research Europe (COHERE) study group
showed that risk factors for death in ARL included low nadir
CD4+ cell counts and a history of injection drug use [4].
4. Treatment of Newly DiagnosedARL
ARLs are aggressive lymphomas and roughly 80% of patients
present with advanced stage disease. Half of these patients
will have gastrointestinal involvement and 30% will have
bone marrow involvement [3, 14]. In addition, approxi-
mately 5 to 20 percent of patients with ARL have spread to
thecentralnervoussystem(CNS)atthetimeofpresentation,
typically in the form of lymphomatous meningitis [34]. It
is not clear that patients with HIV infection are inherently
at higher risk for leptomeningeal involvement. It is more
likely that the high incidence of CNS disease is related to the
greater frequency of extranodal disease and Burkitt histology
[35]. Lymphomatous meningitis may also present at the
time of disease recurrence, particularly in patients at high
risk for occult leptomeningeal involvement not treated with
intrathecal prophylactic therapy during initial treatment of
the lymphoma.
Several prospective studies have reported using regimens
such as cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP); methotrexate, bleomycin, doxorubicin,
cyclophosphamide, vincristine, and dexamethasone (m-
BACOD); infusional cyclophosphamide, doxorubicin, and
etoposide [6, 7, 23, 36]. These studies have combined the
high-grade DLBCL and Burkitt or Burkitt-like lymphoma
subtypes with little diﬀerence in outcome among the
various histologic subtypes. Patients who were most likely
to achieve a complete remission with chemotherapy were
those who had less disease burden, no bone marrow or
CNS involvement, no prior AIDS-deﬁning illness, and an
adequate performance status.
The introduction of HAART has led to dramatic
improvement s in morbidity and mortality for PLWA. Such
individuals now have an OS that is near or comparable to
that of HIV seronegative individuals [21, 37].
The use of HAART has facilitated the use of standard-
dose and even dose-intensive chemotherapy regimens with
reasonable safety to patients with ARL. With use of HAART,
leading to improvements in HIV viral suppression and
patients’ immune status, more recent studies have demon-
strated that patients with ARL can be treated with standard-
dose lymphoma protocols without experiencing undue tox-
icity [10, 23, 38, 39]. In addition, patients with ARL who
receive chemotherapy now achieve a median OS comparable
to the outcome in the non-immunosuppressed population
[21, 23, 24, 40].
TheUnitedStatesNationalCancerInstitute(NCI)-spon-
sored AIDS Malignancy Clinical Trials Consortium (AMC)
compared dose-reduced or full-dose cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP) with con-
comitant HAART with complete remission (CR) of 30% and
48% in the reduced dose and full-dose groups, respectively
[33]. The German ARL study group also reported results
of full-dose CHOP in patients with ARL stratiﬁed into
standard- (0-1 factors) and high- (2-3 factors) risk based on
CD4+ count <50cells/µL, prior OI and performance status
≥3. Standard-risk group patients had a CR of 79%, similar
to that achieved in non-HIV infected patients with similar
histologically aggressive lymphomas, while the CR was 29%
in the high-risk group [32]. A more recent study by Groupe
d’Etude des Lymphomes de l’Adulte (GELA) and Gruppo
Italiano Cooperativo AIDS e Tumori (GICAT) reported
on results of risk-adapted intensive chemotherapy in ARL
patients [30]. A total of 485 patients were randomly assigned
to chemotherapy after stratiﬁcation according to “HIV
score” based on performance status, prior AIDS diagnosis,
and CD4+ count of <100cells/µL. A total of 218 good-
risk patients (HIV score 0) received ACVBP (doxorubicin,
cyclophosphamide,vindesine, bleomycin,andprednisolone)
or CHOP; 177 intermediate-risk patients (HIV score 1)
received CHOP or low-dose CHOP (Ld-CHOP); 90 poor-
risk patients (HIV score 2-3) received Ld-CHOP or VS
(vincristine and steroid). The 5-year OS in the good-risk
group was 51% for ACVBP versus 47% for CHOP; in the
intermediate-risk group, 28% for CHOP versus 24% for Ld-
CHOP; in the poor-risk group, 11% for Ld-CHOP versus
3% for vs. The only signiﬁcant factors for OS were HAART
therapy, HIV score, and the IPI score, but not chemotherapy
regimen, suggesting that in ARL patients, HIV score, IPI
score, and HAART aﬀect survival but not the dose intensity
of the CHOP-based chemotherapy.
Infusional therapy may overcome some drug resistance
and high tumor proliferation in aggressive lymphomas. A
study of infusional dose-adjusted EPOCH (etoposide, pred-
nisone, vincristine, cyclophosphamide, and doxorubicin) in
39 newly diagnosed ARL reported a CR in 74% of patients,
and at a median followup of 53 months, disease-free sur-
vival (DFS), and OS of 92% and 60%, respectively [9].
An alternative infusional regimen which incorporated
CDE (cyclophosphamide, doxorubicin, and etoposide) was
employed by the US Eastern Cooperative Oncology Group
(ECOG). Study (E1494) enrolled 98 patients with ARL. At4 Advances in Hematology
two-year followup a CR of 45% was achieved and failure-free
survival (FFS) and OS were 36% and 43%, respectively [7].
A number of recent clinical trials have further sought to
combine anti-CD20 chimeric monoclonal antibody (ritux-
imab) with ARL-based chemotherapy based on its superior
eﬃcacy when added to treatment of lymphoma in non-HIV
infected patients. In a pooled analysis of three ARL prospec-
tive phase II studies evaluating rituximab in combination
with infusional CDE, the CR was 70% and the estimated 2-
year FFS and OS rates were 59% and 64%, respectively [39].
An increased risk of life-threatening infections was noted;
14% of patients were diagnosed with OIs during or within
3 months of completion of R-CDE, and 8% of patients died
from infectious complications. In the multicenter AMC 010
phase III trial, 150 ARL patients were randomized at a ratio
of 2:1 to receive CHOP and rituximab or CHOP only [10].
Results were provocative—with a median followup of 137
weeks there was a non-statistically signiﬁcant trend towards
improvementintime-to-progression(TTP:125weeksversus
85 weeks), progression-free survival (PFS: 45 weeks versus
38 weeks), and OS (139 weeks versus 110 weeks). Survival
was signiﬁcantly inﬂuenced by CD4+ count and IPI score.
Although there was a trend towards a higher CR rate for
thosepatientstreatedintherituximabarm(58%versus47%,
P = 0.147), there were also substantially more deaths due
to treatment-related infections in the rituximab arm (14%
versus 2%, P = 0.027) with the majority of those deaths
occurringinpatientswithCD4+counts<50cells/µLatstud y
entry.
In contrast to AMC 010, a phase II study from France did
not show an increase in the risk of life-threatening infections
while treating newly diagnosed ARL patients with R-CHOP
[10]. In this cohort of 61 patients, R-CHOP produced a CR
of 77% and a 2-year OS of 75% with only 1 patient death
attributed to infection.
Rituximab has also been evaluated in conjunction with
infusional EPOCH. In a randomized phase II AMC trial
034, rituximab was given either concurrently just before
each infusional EPOCH chemotherapy cycle or sequentially
(weekly for 6 weeks) after completion of all chemotherapy
(4–6 cycles) in ARL [12]. CR was 73% in the concurrent
arm, compared to 55% in the sequential arm. Toxicity was
comparable in the 2 arms, although patients with a baseline
CD4+ <50cell/µL had a high infectious death rate in the
concurrentarm.Theinvestigatorsconcludedthatconcurrent
rituximab and infusional EPOCH is an eﬀective regimen
for ARL that merits further evaluation, but that caution is
needed for those patients with severe immunodeﬁciency.
To summarize, rituximab has been shown to improve re-
sponse rates and overall survival for patients with aggressive
NHL who were HIV negative and treated with CHOP, with-
out an increased risk of infectious complications. Rituximab,
when given sequentially with chemotherapy, is associated
with improved control of ARL; however, in a single clinical
trial, the use of rituximab accounted for a higher risk of
severe infection than has been seen for patients with NHL
who were HIV negative. Several more recent ARL studies
combining chemotherapy with rituximab have not, however,
led to an increased risk of death due to infectious complica-
tions.
Most oncologists favor administration of rituximab with
chemotherapy, although caution should be exercised for
using rituximab in severely immunosuppressed patients
with CD4+ counts of less than 50cells/µL. Mature results
from an ECOG study which randomizes non-HIV-infected
patients with DLBCL to R-EPOCH or RCHOP will likely
inﬂuence the way ARL is treated [41]. R-CHOP is more
commonly oﬀered in community settings because of ease
of administration, because of physician familiarity with
this regimen, and because no other regimen has, in a
randomized and prospective study, outperformed R-CHOP
for the treatment of DLBCL. However, oncologists who
have substantial experience with infusional therapy may rea-
sonably choose R-EPOCH based on favorable phase II data.
Several ongoing clinical trials are evaluating novel chem-
otherapeutic combinations with biologic agents in this set-
ting of ARL as listed in Table 2.
The appropriate timing of institution of HAART in
relationship to multiagent chemotherapy has been evaluated
in several clinical trials but with no clear answers. In a
small study involving ARL patients, antiretroviral control
was a signiﬁcant factor in the ability to attain CR [38]. In
a more recent trial evaluating safety and eﬃcacy of liposomal
doxorubicin when substituted for doxorubicin in the CHOP
regimen eﬀective HIV viral control during chemotherapy
was associated with signiﬁcantly improved survival, but
CRs were attained independent of HIV viral control [23].
The AMC 010 study reported the feasibility of combining
R-CHOP with concomitant HAART in 65 patients. Only
one OI occurred during chemotherapy administration.
Cyclophosphamide clearance was reduced compared with
historical controls, without clinical signiﬁcance. Additional
studies of CHOP-based chemotherapy and HAART have
yielded median survival periods of approximately 2 years
[27, 29, 42]. For patients who continue HAART while
receiving chemotherapy, CD4+ cell counts decline by 50%,
but these values gradually improve and typically return to
baseline within 6 months to 1 year of completing lymphoma
treatment[43]. For patients who continue to receive eﬀective
HAART during chemotherapy, HIV viral replication tends
to remain suppressed below the limits of detection using
commercial-based polymerase chain reaction assays.
Chemotherapy without concomitant antiretroviral ther-
apy also has been studied in the HAART era. Reasons for
HAART omission include concerns of drug interactions with
chemotherapy and poor patient adherence because of nausea
or vomiting. This could lead to heightened toxicity and the
emergence of multidrug-resistant HIV quasispecies. In the
NCI EPOCH study, HIV viral load increased and CD4+ cell
counts decreased while patients received chemotherapy, but
both parameters improved rapidly following the reintroduc-
tion of HAART at the completion of chemotherapy [12].
In the hands of experienced investigators, the temporary
discontinuation of HAART for 4 to 6 months, while patients
received chemotherapy did not lead to persistent and delete-
rious immunologic consequences. It is acceptable, therefore,
to withhold HAART for a brief period of several monthsAdvances in Hematology 5
Table 2: Active clinical trial protocols evaluating chemotherapy in ARL.
Study identiﬁer Phase Study regimen Start date Primary endpoint
NCT00006436 II EPOCH and Rituximab in ARL October 2000 PFS
NCT00598169 (AMC 053) I/II Bortezomib, Ifosfamide, Carboplatin, and
Etoposide ± Rituximab in relapsed ARL
November 2007 ORR and safety
NCT01092182 II Dose-adjusted R-EPOCH in Burkitt or
c-MYC+ DLBCL
February 2010 PFS, EFS, and OS
NCT01193842 (AMC 075) I/II R-CHOP or R-EPOCH ± Vorinostat in
AIDS-related DLBCL
October 2010 ORR, MTD, and toxicity
EPOCH: etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; ARL: AIDS-related lymphoma; PFS: progression-free survival; AMC: AIDS
Malignancy Consortium; ASCT: autologous stem cell transplant; PET: positron emitting tomography; CT: computed tomography; ABVD: doxorubicin,
bleomycin,vinblastine,dacarbazine;BEACOPP:bleomycin,etoposide,doxorubicin,cyclophosphamide,vincristine,procarbazine,prednisone;HL:Hodgkin’s
lymphoma; OS: overall survival; ORR: overall response rate; DLBCL: diﬀuse large B cell lymphoma; EFS: event-free survival; R-CHOP: rituximab,
cyclophosphamide, doxorubicin, vincristine, prednisone; MTD: maximum tolerated dose.
Source: http://clinicaltrials.gov/.
while patients receive ARL chemotherapy. In the absence of a
head-to-head trial of administering or withholding HAART,
both approaches are reasonable. HAART may, however, be
particularly attractive to oﬀer concurrently with chemother-
apy for those patients who have a depleted CD4+ cell count
at the time of ARL diagnosis, a history of opportunistic
infectionsorotherAIDS-relatedcomplications,appearlikely
to adhere to taking multiple oral medications, and for those
patients who would likely achieve a nondetectable HIV viral
load with HAART.
5.Treatment of BurkittandBurkitt-LikeNHL
Prospective studies of ARL generally have combined the
high-grade DLBCL and Burkitt lymphoma/Burkitt-like lym-
phoma histologies, with little diﬀerence in outcome between
the subtypes. In contrast, two retrospective reviews demon-
strated substantially inferior outcomes for AIDS-associated
Burkitts lymphoma in the HAART era in comparison with
HIV-associated DLBCL when CHOP-like treatments were
used [44]. Median survival was 5.7 months and 8 months for
those with Burkitts lymphoma compared with 43.2 months
and 22 months for those with DLBCL who received CHOP-
like chemotherapy in the HAART era. Small retrospective
and phase II studies of AIDS-associated Burkitt lymphoma
reported the feasibility of using dose-intensive protocols
with or without HAART treatment with response rates of
approximately 70% [25, 45]. In addition, the NCI recently
presented preliminary ﬁndings of abbreviated (three) cycles
ofdose-adjustedR-EPOCHinconjunctionwithprophylactic
intrathecal CNS therapy for eight patients with AIDS-
related Burkitt lymphoma [46]. All patients achieved a CR
and remained in remission with a median followup of 4
years. These preliminary but encouraging results have led
investigators to reconsider how best to treat HIV-infected
patients with Burkitt lymphoma. AMC Study 048 recently
completed accrual of patients with AIDS-related Burkitt
lymphoma into a phase II study of high-dose, short-course
chemotherapy regimen consisting of rituximab, cyclophos-
phamide, doxorubicin, vincristine, intrathecal cytarabine
and methotrexate, ifosfamide, and etoposide (R-CODOX-
M/IVAC). Final results from this study have yet to be
reported. For patients with AIDS-related Burkitt lymphoma
who have an adequate Karnofsky performance status an
adequate CD4+ cell count and well-controlled HIV viremia,
anintensivechemotherapyregimensimilartowhatisoﬀered
to patients with Burkitt lymphoma who are HIV negative is
recommended.
6.Treatment ofRelapsedARL
Optimal chemotherapy for patients with relapsed/refractory
ARL has not been deﬁned and such patients are usually
treated with regimens that are used for non-HIV-infected
patients with relapsed/refractory aggressive lymphoma, such
as ifosfamide, cisplatin and etopside (ICE), or etopo-
side, solumedrol, high-dose cytosine arabinoside, platinum
(ESHAP) [47, 48]. These patients can also be considered
for high-dose chemotherapy (HDCT) and peripheral autol-
ogous stem cell transplant (ASCT) if they have chemo-
sensitive disease and have not exhausted HAART options.
HAART therapy is feasible throughout the transplant pro-
cess. In one report, 16 of 19 patients remained in remission
after 2 years of followup [49]. Infectious complications were
comparable with those that have been reported in the HIV-
negative NHL patients who underwent ASCT and no long-
term deterioration in immune function was noted. Several
studies have reported success in the treatment of relapsed
ARL using second-line therapy followed by HDCT and
ASCT [50–52]. Among 68 ARL patients who underwent
HDCT/ASCT from 20 institutions across Europe between
the years 1999 and 2004, the PFS and OS were 56.5% and
61%, respectively, at a median followup of 32 months [53].
In a prospective study of HDCT/ASCT conducted by the
GICAT group, 27 of the 50 enrolled patients underwent
ASCT [54]. Intention-to-treat analysis showed a superior
median OS for those who underwent ASCT (44 versus
33 months) compared to those who did not. Response to
therapy signiﬁcantly aﬀected OS. In addition, AMC inves-
tigators used a preparative regimen of reduced-dose oral or
intravenousbusulfaninconjunctionwithcyclophosphamide
as a preparative regimen for ASCT in patients with recurrent
ARL and Hodgkin lymphoma [52]. The mean time to
achievement of an absolute neutrophil count of greater than6 Advances in Hematology
Table 3: Active clinical trial protocols evaluating hematopoietic stem cell transplant in ARL.
Study identiﬁer Phase Study Start date Primary endpoint
NCT00345865 II
Cyclophosphamide + TBI versus
carmustine, cyclophosphamide and
etoposide conditioning followed by ASCT in
AIDS-related NHL or HL
November 2005 DFS and OS
NCT00641381 II Carmustine, Etoposide, Cyclophosphamide
and ASCT in ARL March 2000 Feasibility and
toxicity
NCT00858793 I/II HDT and transplantation of gene-modiﬁed
ASCT for high-risk ARL October 2008 Adverse events
NCT00968630 II
Immune response after HSCT in
HIV-positive patients with hematologic
cancer
August 2009 HIV-speciﬁc
immune response
NCT01045889 II R-CHOP followed by HDT and ASCT January 2007 OS
NCT01141712 (AMC
071) II HDT (BEAM) and ASCT in ARL February 2011 OS
NCT01410344 II
Allogeneic HSCT for hematological cancers
and myelodysplastic syndromes in
HIV-infected individuals
September 2011 NRM
TBI: total body irradiation; NHL: non-Hodgkin’s lymphoma; HL: Hodgkin’s lymphoma; DFS: disease-free survival; OS: overall survival; HDT: high-dose
therapy; ASCT: autologous stem cell transplant; HSCT: hematopoietic stem cell transplant; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine,
prednisone; BEAM: carmustine, etoposide, cytarabine, melphalan; NRM: nonrelapse mortality.
Source: http://clinicaltrials.gov/.
0.5 × 109/ Lw a s1 1d a y s( r a n g e ,9t o1 6d a y s ) .T h em e d i a n
time to achievement of an unsupported platelet count of
at least 20 × 109/ Lw a s1 3d a y s( r a n g e ,6t o5 7d a y s ) .O n e
patient died on day +33 after ASCT as a result of hepatic
and renal occlusive disease and multiorgan failure. No other
fatal regimen-related toxicity occurred and 10 (53%) of 19
evaluable patients were in complete remission at day +100.
Recently, investigators from the City of Hope compared
their experiences treating 29 consecutive patients with re-
lapsed or progressive ARL who underwent ASCT to age,
gender, histology, and stage-matched NHL controls who
also underwent ASCT [55]. The median ARL patient age
was 42 years and DLBCL/anaplastic large cell (16 patients)
and Burkitt (11 patients) histologies predominated. The
conditioning regimen most commonly consisted of CBV
(cyclophosphamide 100mg/kg, carmustine 450mg/m2,a n d
etoposide 60mg/kg). The median time to engraftment was
10 days (range, 5–19 days). Treatment-related toxicities
between the groups were comparable and 2-year overall
survival at 75% was the same for both groups.
European investigators have also reported results involv-
ing 53 HIV-positive and 53 HIV-negative matched lym-
phomapatientswhounderwentASCT[20].IncidenceofPFS
and OS were similar in both cohorts. The authors concluded
that HIV-infected patients should be considered for ASCT
according to the same criteria adopted for HIV-negative
NHL patients. Furthermore, long-term followup data of
ARL patients undergoing ASCT showed the nonrelapsed
mortality (11% versus 4%, P = 0.18), 2-year DFS (76%
versus 56%, P = 0.33) and the 2-year point estimates
of OS (74% versus 75%, P = 0.93) were comparable to
matched HIV-negative NHL controls [55] .T h e s es t u d i e sa r e
preliminary but published experience with ASCT for ARL
is accumulating [20, 52, 56–59]. Larger studies (some of
which are currently underway, Table 3) with longer followup
are needed to better deﬁne the optimal ARL conditioning
regimen and to better delineate patient selection criteria.
Gene therapy is an emerging technology that holds
promise for patients with relapsed ARL. Recently, a stable ex-
pression of a lentiviral vector encoding anti-HIV RNAs in
blood stem cells was transplanted into four such patients
who were undergoing HDT followed by ASCT [60]. They
each received gene-modiﬁed hematopoietic progenitor cells
expressing 3 RNA-based anti-HIV moieties (tat/rev short
hairpin RNA, TAR decoy, and CCR5 ribozyme). The gene-
modiﬁed cells showed no diﬀerences in their hematopoietic
potential compared with nontransduced cells; by day +11
all four patients were successfully engrafted with a persistent
expression of the vector and the introduced small interfering
RNA and ribozyme.
7. Supportive Careand
Late-Treatment Complications
Attention to supportive care measures is essential for pa-
tients with ARL. Judicious use of hematopoietic stimulants
including the newest formulation of pegylated granulocyte-
colony stimulating factor (G-CSF) may help ameliorate
chemotherapy-induced neutropenia.
The US Food and Drug Administration (FDA) has issued
a warning to medical providers that erythropoiesis-stim-
ulating agents (darbepoetin alfa and epoetin alfa) are as-
sociated with a high rate of thrombosis for patients withAdvances in Hematology 7
cancer [61]. For these patients, the use of erythropoiesis-
stimulating agents also may lead to a heightened risk of
cancer progression and death [62]. Until these concerns are
m o r ef u l l ye v a l u a t e d ,i ti sb e s tt ot r a n s f u s ep a c k e dr e db l o o d
cells when patients with ARL develop symptomatic anemia.
To minimize cardiac toxicities, pegylated anthracyclines
have been used for the treatment of ARL, and liposomal
anthracyclines also may oﬀer some of the pharmacokinetic
beneﬁts of infusional doxorubicin but without the need for
patients to be connected to cumbersome infusion pumps for
several days’ duration. Single institution studies suggested
thatsubstituting liposomal anthracyclinesfordoxorubicin in
multiagent lymphoma protocols was both safe and eﬀective
[23, 63]. AMC Study 047 substituted liposomal doxorubicin
for doxorubicin in the R-CHOP regimen for patients with
ARL[64].However,adisappointing CRrateofonly37%was
achieved.
Infectious complications associated with ARL may be
minimized by using prophylactic ﬂuroquinolone antibiotics
and azoles during periods of protracted neutropenia. All
patients should receive Pneumocystitis jiroveci prophylaxis
(e.g., dapsone, inhaled pentamidine, atovaquone) regardless
of initial CD4+ cell count. Trimethoprim-Sulfamethoxazole
is infrequently used because of its potential to exacerbate
myelosuppresasion.
With longer life expectancy following chemotherapy,
late-treatment-related complications are emerging as a
serious concern after treatment for ARL. Chemotherapy-
related acute myelogenous leukemia (11q21 deletion with 2
additional copies of MLL gene at 10q) has been reported in
an HIV-positive individual 48 months after therapy with R-
EPOCH for ARL [65]. Similarly, three cases of secondary
malignancy in the setting of ASCT have been reported
[53]. It remains unknown whether the rate of secondary
malignancies is intrinsically increased in the setting of HIV
infection.
8. Concluding Remarks
Epidemiologic reports clearly indicate that the incidence of
ARL has decreased since the introduction of HAART among
patients with AIDS. Chemo-immunotherapy for the most
common subtype of ARL, DLBCL, is improving, with several
phase II clinical trials showing good outcomes employing
R-CHOP or R-EPOCH. CR rates for those patients with
good prognosis features rival those of similarly matched
non- HIV infected patients with DLBCL. Better supportive
care, employing the use of G-CSF, prophylactic antibiotics,
and HAART either during or shortly after completion of
chemotherapy may ameliorate the increased toxicity of
concurrent immunotherapy, thereby improving survival of
patients with ARL. Clinical trials investigating the role
of autologous and allogeneic HSCT in relapsed/refractory
ARL are currently underway. With eﬀective treatments and
longer life expectancy following chemotherapy, late-treat-
ment-related complications are emerging, and how best to
mitigate and manage these complications is an emerging
challenge.
Abbreviations
AIDS: Acquired immunodeﬁciency syndrome
HAART: Highly active antiretroviral therapy
ARL: AIDS-related lymphoma
HIV: Human immunodeﬁciency virus.
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